RxDoctor Payments Data

Parween Moness, MD

Internal Medicine · El Dorado Hills, CANPI 1326066119

Payments from drug & device makers

$747in general payments, 2019–2025

Across 42 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$230
  • Novo Nordisk$94
  • AbbVie$82
  • Mayne Pharma Commercial LLC$66
  • Lilly USA, LLC$54
  • Bausch Health US, LLC$41
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$747100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$747 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$156,584
Medicare patients
249
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$71,542
OzempicSemaglutide60$60,883
JardianceEmpagliflozin36$43,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$38,805
MyrbetriqMirabegron26$26,187
MounjaroTirzepatide24$23,979
JanuviaSitagliptin Phosphate22$23,706
LinzessLinaclotide27$18,176
Repatha SureclickEvolocumab16$15,388
BelsomraSuvorexant14$9,400
SymbicortBudesonide/Formoterol Fumarate18$7,435
Atorvastatin Calcium459$6,432
Combivent RespimatIpratropium/Albuterol Sulfate11$6,059
Levothyroxine Sodium382$5,201
SynthroidLevothyroxine Sodium55$4,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$20$72,971116 claims
Novo NordiskOzempic$94$60,88360 claims
Boehringer IngelheimJardiance, Combivent Respimat$20$49,47747 claims
GSKTrelegy Ellipta$16$38,80533 claims
Astellas Pharma US IncMyrbetriq$23$26,18726 claims
Lilly USA, LLCMounjaro$54$23,97924 claims
AbbVieLinzess, Synthroid$82$22,80082 claims
AstraZenecaSymbicort$230$7,43518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in El Dorado Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →